Longevity & Aging · Metabolic & Cardiometabolic
testosterone therapy decreases fat mass
In plain terms: Does testosterone therapy help you lose fat?
Leans support Longevity & Aging 🔬 Includes disconfirming
Part of: 💊 Testosterone therapy (TRT)
RefutedContestedStrong support
consensus score 0.59
Somewhat — it tends to trim fat (especially belly/visceral fat) and add muscle, shifting your body composition. But it's not a weight-loss drug: several trials, especially in obese or dieting men, found no real difference in fat or scale weight versus placebo.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
11 support 2 contradict 3 tested null 2 mixed · 18 sources, 13 independent groups
What the evidence shows
Testosterone therapy tends to shift body composition — modestly lowering fat mass (especially visceral/abdominal fat) while raising lean mass — but the fat-loss effect is smaller and less consistent than the muscle effect. Several trials, particularly in obese men or men also dieting, found no significant difference in total fat or body weight versus placebo.
The evidence (19)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Azzi M, Lami A, Dones A, Cicero AFG, Siconolfi A, Seracchioli R, Meriggiola MC 2026 · Journal of endocrinological investigation | observational | contradicts | moderate | 57 transmasculine adults followed 10 years on testosterone-based GAHT; weight, BMI, and waist circumference increased, and body composition showed higher trunk (android) fat distribution, not a fat-mass reduction. |
| Gopal RA, Bothra N, Acharya SV, Ganesh HK, Bandgar TR, Menon PS, Shah NS 2010 · Andrologia | RCT | tested-null | low | Crossover RCT (T2DM): no significant effect on insulin resistance, visceral fat, or anthropometrics. |
| Shigehara K, Shinzawa R, Sakatoku N, Nohara T, Izumi K, Namiki M, Mizokami A 2026 · International journal of urology : official journal of the Japanese Urological Association | RCT | supports | moderate | 214 hypogonadal men in 4 arms (TRT+exercise, TRT-alone, exercise-alone, control); body fat percentage significantly decreased only in the TRT+exercise group at 6 months, over 1 year of testosterone enanthate 250mg IM. |
| Junjie W, Dongsheng H, Lei S, Hongzhuo L, Changying S 2019 · Curr Pharm Des | meta-analysis | contradicts | low | Meta-analysis of 7 RCTs, 800 older men with low serum testosterone: null on fat mass. The paper reports T therapy 'had no statistical effect on prostate symptoms, body composition, serum hormones and metabolism' and concludes 'it has limited effects on ... body mass index (BMI), fat mass'. A null on a directional (decreases-fat-mass) claim is contradicts, not tested-null. Caveat carried: no pooled estimate, CI or heterogeneity is reported for fat mass in the available text (abstract only; Bentham full text paywalled), so the null is authors' prose, unquantified. Separately and on a different object, the same paper found lean mass increased. |
| Seminara G, Leuzzi M, Meduri L, Greco EA, Aversa A 2026 · Minerva endocrinology | RCT | supports | moderate | 10 obese hypogonadal 'late responder' men on tirzepatide; adding testosterone undecanoate 1000mg IM for 6 months produced significantly greater fat-mass reduction than tirzepatide alone (group B vs A, P<0.05). |
| Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS 2004 · J Clin Endocrinol Metab | RCT | supports | moderate | Long-term trial (n=163): lean mass up, fat mass down (both p=0.0001) maintained up to 42 months. |
| Guo C, Gu W, Liu M, Peng BO, Yao X, Yang B, Zheng J 2016 · Exp Ther Med | meta-analysis | tested-null | moderate | Fat-mass pool = 5 of the 16 RCTs, 995 participants (503 treated / 492 control): MD -0.85 kg (95% CI -1.74 to 0.04, P=0.06) - underpowered trend toward the claim (point estimate favours fat loss, interval includes zero), graded tested-null per CONVENTIONS §5 second clarification; both route subgroups sit on the same side (transdermal -0.91, CI -1.91 to 0.08, P=0.07; injection -0.6, CI -2.6 to 1.4, P=0.56). Body weight (5 RCTs/841) MD 0.09 and BMI (6 RCTs/633) MD 0.10 were flat nulls. Fixed-effects pooling; funnel plot showed no publication bias. |
| Ng Tang Fui M, Hoermann R, Prendergast LA, Zajac JD, Grossmann M 2016 · BMC Med | RCT | tested-null | moderate | RCT (obese, dieting): no difference in weight loss between TRT and placebo; symptomatic benefit only. |
| Griffith A, Perlman A, Karr T, Thompson ME, Kolterman O 2025 · Frontiers in endocrinology | n-of-1 | mixed | low | Single 52-year-old male on TRT plus lifestyle/probiotic intervention over 6 months; fat mass decreased 13.2 lb (~6 kg) with a 6.1% reduction in body-fat percentage. |
| Christensen LL, Poulsen HE, Andersen MS, Glintborg D 2023 · J Clin Endocrinol Metab | RCT | supports | moderate | RCT (aging men): TRT reduced whole-body fat and subcutaneous adipose tissue vs placebo (24 weeks). |
| Korkmaz ES et al 2026 · Endocrine research | observational | supports | low | 15 transgender men on intramuscular testosterone for 12 months; body fat percentage decreased significantly while fat-free mass and weight increased (small retrospective cohort, no kg figure given). |
| Aversa A, Bruzziches R, Francomano D, Rosano G, Isidori AM, Lenzi A, Spera G 2010 · J Sex Med | RCT | supports | moderate | RCT (metabolic syndrome): TRT reduced waist circumference and visceral fat over 24 months; improved HOMA-IR. |
| Neto WK, Gama EF, Rocha LY, Ramos CC, Taets W, Scapini KB, Ferreira JB, Rodrigues B, Caperuto É 2015 · Age (Dordr) | meta-analysis | supports | moderate | Meta-analysis of RCTs in men >60y with total T <=550 ng/dl: 11 studies included, 8 pooled. Fat mass decreased, effect estimate -1.78 kg [-2.57, -0.99] (interval excludes null), with high heterogeneity I2=81%. PubMed-only search closed 2013-10-04. |
| Barnouin Y, Armamento-Villareal R, Celli A, Jiang B, Paudyal A, Nambi V, Bryant MS, Marcelli M, Garcia JM, Qualls C, Villareal DT 2021 · J Clin Endocrinol Metab | RCT | mixed | moderate | RCT (obese frail >=65y): TRT attenuated but did not reverse diet-induced lean/BMD loss; no overall function benefit. |
| Mangolim AS, Brito LAR, Nunes-Nogueira VDS 2022 · Eur J Endocrinol | meta-analysis | supports | moderate | Systematic review + random-effects meta-analysis, 16 RCTs, men with obesity AND low testosterone levels; GRADE-rated, dual reviewers, prediction intervals and meta-regression reported. On this claim's object the paper reports: 'TRT was effective for waist circumference and BMI; however, large between-study heterogeneity was found, with 95% prediction intervals crossing the null effect line.' Fat mass in kg is NEVER reported - the measured adiposity endpoints are waist circumference and BMI only, and no trial count or participant denominator is given for either pool (the available text does not say; the only endpoint carrying its own denominator anywhere in the abstract is cardiovascular events, 7 trials / 583 participants). Stance is supports, not mixed: the pooled effect points one way on the object and nothing in the paper points against it - the wide prediction intervals are an imprecision and generalisability limitation, not a disconfirming result, and the lean-mass and LDL findings the prior extract led with are OTHER claims' objects. The authors' own condition is part of the finding, not a caveat to drop: 'Meta-regression revealed that the average age of participants was a significant modifier for both outcomes' and 'The mean age of participants significantly modified the effect of TRT on weight loss' - which age band benefits is not stated in the abstract. Quality moderate: author-reported large between-study heterogeneity in their own result forecloses high. Abstract-grade; not in the PMC open-access subset. |
| Kolla B, Kalra P 2025 · Indian J Med Res | observational | supports | low | Single-arm prospective cohort with no control group; 21 of 22 transmen analysed at 12 months on testosterone enanthate. The measured endpoint is bioimpedance body-fat PERCENTAGE, not fat mass in kg (no weight or kg-fat figure is reported anywhere), and the percentage fell while muscle mass rose in the same participants. Total subcutaneous fat fell in both modes (cis 34.19 to 31.31%, trans 34.49 to 32.22%, P<0.001 in both), but visceral fat did not change (P=0.600 cis, P=0.227 trans). Authors state BIA falls short of the precision of DXA. |
| Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A 2005 · Clin Endocrinol (Oxf) | meta-analysis | supports | high | Random-effects meta-analysis of 29 RCTs, 1,083 middle-aged and ageing men (625 randomized to T, 427 to placebo, 31 to observation; weighted mean age 64.5 years, mean serum testosterone 10.9 nmol/l): 'Testosterone treatment produced: (i) a reduction of 1.6 kg (CI: 2.5--0.6) of total body fat, corresponding to -6.2% (CI: 9.2--3.3) variation of initial body fat, (ii) an increase in fat free mass of 1.6 kg (CI: 0.6--2.6), corresponding to +2.7% (CI: 1.1--4.4) increase over baseline and (iii) no change in body weight.' The no-change-in-body-weight clause is part of the same finding, not a caveat to drop: fat fell 1.6 kg while fat-free mass rose by the same 1.6 kg, so this is recomposition rather than weight loss - which is exactly the honesty caveat the claim already carries. DENOMINATOR: 1,083 / 29 RCTs is the total across body-composition, strength, bone and lipid endpoints; the number of trials contributing the body-fat pool is not stated and is the available text does not say. Endpoint is total body fat by the pooled trials' own methods; no visceral or abdominal fat estimate appears in the abstract. Abstract-grade (not in the PMC open-access subset). |
| Gruenewald DA, Matsumoto AM 2003 · J Am Geriatr Soc | observational | supports | low | Systematic review: TRT increases lean mass and reduces fat mass in healthy older men with low-normal T. |
| Kapoor D, Goodwin E, Channer KS, Jones TH 2006 · Eur J Endocrinol | RCT | supports | moderate | Crossover RCT (T2DM hypogonadal): TRT reduced waist circumference (-1.63 cm) and waist/hip ratio. |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.